- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Nexalin Technology, Inc.: Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS Platform | 1 | GlobeNewswire (USA) | ||
| 17.06. | Nexalin Technology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.06. | Nexalin Technology, Inc.: Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life ... | 185 | GlobeNewswire (Europe) | Study using Nexalin's proprietary DIFS 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results... ► Artikel lesen | |
| NEXALIN TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 10.06. | EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life | 2 | Benzinga.com | ||
| 04.06. | Nexalin receives U.S. patent for neurostimulation method | 1 | Investing.com | ||
| 04.06. | Nexalin erhält US-Patent für Neurostimulationsverfahren gegen Angst, Depression und Schlaflosigkeit | 1 | Investing.com Deutsch | ||
| 04.06. | Nexalin Technology, Inc.: Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia | 185 | GlobeNewswire (Europe) | Newly issued U.S. patent expected to provide core intellectual property protection through 2042, further strengthening Nexalin's proprietary position in non-invasive frequency-based deep-brain neurostimulation... ► Artikel lesen | |
| 27.05. | Nexalin Technology: EPS übertrifft Schätzungen - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 21.05. | Nexalin: $1.3 Million PONM Acquisition Expands AI-Integrated Neurostimulation Platform Ahead Of FDA Trial | 1 | pulse2.com | ||
| 21.05. | Nexalin Technology, Inc.: Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for ... | 3 | GlobeNewswire (USA) | ||
| 19.05. | Nexalin Technology, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Nexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial | 397 | GlobeNewswire (Europe) | HOUSTON, TX, May 19, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( (Nasdaq: NXL) ("Nexalin" or the "Company"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 08.05. | Nexalin Technology, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.04. | Nexalin Technology, Inc.: Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia | 2 | GlobeNewswire (USA) | ||
| 22.04. | Nexalin Technology, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | Nexalin announces pivotal insomnia trial, targets Q2 enrollment | 1 | Investing.com | ||
| 22.04. | Nexalin Technology, Inc.: Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment | 269 | GlobeNewswire (Europe) | HOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 15.04. | Nexalin Technology, Inc.: Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China | 263 | GlobeNewswire (Europe) | HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS) of the... ► Artikel lesen | |
| 09.04. | Nexalin Technology, Inc.: Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents | 1 | GlobeNewswire (USA) | ||
| 09.04. | EXCLUSIVE: Nexalin Study Flags Reduced Self-Injury In Adolescents Using Brain Stimulation Device | 2 | Benzinga.com |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PLUS THERAPEUTICS | 3,620 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics to Provide Business Update Call on June 30, 2026 | ||
| ORGANON | 11,790 | +0,55 % | Organon and Henlius launch Prolia and Xgeva biosimilars in Canada | ||
| QUIDELORTHO | 10,505 | -2,78 % | QuidelOrtho Corporation: QuidelOrtho Appoints Micah Young as Chief Financial Officer | Seasoned medical technology finance executive brings more than two decades of leadership at global public companies SAN DIEGO, June 23, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq:... ► Artikel lesen | |
| NANO-X IMAGING | 1,520 | -6,17 % | Nano-X Imaging Ltd: Nanox Announces Distribution Agreement with NuvioDx to Support Deployment of Nanox.ARC Systems | Advances Nanox's ongoing U.S. commercialization and deployment efforts PETACH TIKVA, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Nano X Imaging Ltd. ("Nanox", or the "Company", NASDAQ: NNOX), a leader... ► Artikel lesen | |
| ROCKWELL MEDICAL | 0,600 | +1,69 % | ROCKWELL MEDICAL, INC. - 8-K, Current Report | ||
| NUWELLIS, INC | 0,127 | -2,62 % | Nuwellis, Inc.: Nuwellis Appoints Mike McCormick as Chief Executive Officer | MINNEAPOLIS, June 16, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces the... ► Artikel lesen | |
| NYXOAH | 1,410 | +6,33 % | Nyxoah Receives $15 Million from the European Investment Bank | Nyxoah Receives $15 Million from the European Investment Bank Non-dilutive debt funding complements the Company's June equity raise, bringing total capital raised to $110 million Mont-Saint-Guibert... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 20,600 | -2,18 % | PROCEPT BioRobotics Reports First Quarter 2026 Financial Results | SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| NEURONETICS | 1,055 | +0,96 % | Neuronetics, Inc. - 8-K, Current Report | ||
| PULSE BIOSCIENCES | 23,000 | +1,77 % | Pulse Biosciences, Inc.: Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation | U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary... ► Artikel lesen | |
| PROGYNY | 26,610 | +1,26 % | Truist raises Progyny stock price target to $33 on growth outlook | ||
| OPTIMIZERX | 4,565 | -2,46 % | OptimizeRx Corporation: OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance | - Q1 revenue totals $19.8 million- Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively- 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance... ► Artikel lesen | |
| ORTHOFIX MEDICAL | 7,550 | -5,03 % | Orthofix Medical Inc. - 8-K, Current Report | ||
| PAVMED | 4,140 | -4,39 % | PAVmed Inc.: PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results | Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission
Lucid Diagnostics continued building... ► Artikel lesen | |
| OWLET | 5,310 | +4,73 % | Owlet (OWLT) Moves 7.3% Higher: Will This Strength Last? |
NEXALIN TECHNOLOGY INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,006 (-1,69 %) liegt der Kurs bei 0,366 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXALIN TECHNOLOGY INC finden Sie auf Wallstreet Online.